The relationship of serum CX3C chemokine ligand 1 and type Ⅰ plasmin activator inhibitor levels with the severity and prognosis of chronic obstructive pulmonary disease patients with type Ⅱ respiratory failure
Ma Qian
Li Zhicheng
Zeng Yang
Long Bi
Jiang Bing
Abstract：Objective To study the serum levels of CX3C chemokine ligand 1(CX3CL1),type Ⅰ plasmin activator inhibitor(PAI-1)and their relationship with severity and prognosis in chronic obstructive pulmonary disease(COPD)patients with type Ⅱ respiratory failure.Methods Totally 96 patients with COPD combined with type Ⅱ respiratory failure admitted to Yongchuan Hospital of Chongqing Medical University from January 2019 to January 2021 were selected(respiratory failure group),60 patients with simple COPD at the same time were selected as the simple COPD group,and 60 healthy individuals undergoing physical examinations at the same time were selected as the healthy control group.Serum levels of CX3CL1 and PAI-1 of subjects were detected.The differences in serum levels of CX3CL1 and PAI-1 in subjects with different health conditions and patients in respiratory failure group with different severity levels were compared.The factors affecting the poor prognosis of COPD patients with type Ⅱ respiratory failure and the predictive value of serum CX3CL1 and PAI-1 in poor prognosis of COPD patients with type Ⅱ respiratory failure were analyzed.Results The serum levels of CX3CL1 and PAI-1 in the respiratory failure group and the simple COPD group were higher than those in the healthy control group[(266±29),(219±35)ng/L vs(156±23)ng/L;(15.2±2.3),(12.3±2.2)μg/L vs(8.2±1.8)μg/L],and the respiratory failure group was higher than the simple COPD group(all P＜0.05).The serum levels of CX3CL1 and PAI-1 in the mild,moderate and severe groups of respiratory failure group showed upward trends(all P＜0.05).The serum levels of CX3CL1 and PAI-1 in COPD patients with type Ⅱ respiratory failure were negatively correlated with forced expiratory volume in the first second as a percentage of expected value and forced expiratory volume in the first second accounted for forced vital capacity(all P＜0.001).The serum levels of CX3CL1 and PAI-1 in the poor prognosis group of respiratory failure group were higher than those in the good prognosis group(both P＜0.05).Multivariate Logistic regression analysis showed that elevated levels of serum CX3CL1 and PAI-1 were independent risk factors for poor prognosis in COPD patients with type Ⅱ respiratory failure(both P＜0.001).The area under the curve of the combination of serum CX3CL1 and PAI-1 for predicting poor prognosis in COPD patients with type Ⅱ respiratory failure was larger than serum CX3CL1 and PAI-1 alone(both P＜0.001).Conclusions The elevated levels of serum CX3CL1 and PAI-1 in COPD patients with type Ⅱrespiratory failure are related to the severity of the condition.The combined detection of serum CX3CL1 and PAI-1 can help to evaluate the clinical prognosis of COPD patients with type Ⅱ respiratory failure.
Keywords：Chronic obstructive pulmonary diseaseCX3C motif chemokine ligand 1Type Ⅰ plasmin activation inhibitorType Ⅱ respiratory failure
Publication Date：2024-04-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 505-509 )